Literature DB >> 19258952

A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors.

Margaretha Akeson1, Anne-Marie Jakobsen, Britt-Marie Zetterqvist, Erik Holmberg, Mats Brännström, György Horvath.   

Abstract

Epithelial ovarian cancer (EOC) is the major gynecologic cancer mortality cause in Sweden. The aim of the present study was to investigate the long-term survival and prognostic factors of a complete population-based 5-year cohort of 682 patients with invasive EOC in western Sweden (population around 1.6 million). Data relating to residual tumor after surgery, FIGO stage, grade, histopathologic subtype, ploidy status, adjuvant chemotherapy (the prepaclitaxel period), and disease state (recurrence and death) were reported to a quality register in a prospectively kept database and were controlled against the Swedish National Cancer Registry for completeness. The median follow-up durations for the prospectively collected data in the Cox analysis and for the survival analysis that was made for all patients were 81 months (range, 52-109 months) and 11.7 years (range, 8.7-14.1 years), respectively. No patient was lost to follow-up. The relative 10-year survival rate was 38.4% (95% confidence interval, 34.5%-42.8%). The median relative survival time was 4.3 years (95% confidence interval, 3.6%-5.2%). In the univariate Cox regression analysis, prognostic significances for age, stage, residual tumor, histopathologic subtype of serous cystadenocarcinoma, grade, CA-125, and ploidy status were seen. In the multivariate analysis, age, stage, residual tumor after surgery, and postoperative CA-125 were of prognostic significance. In conclusion, 4 major prognostic factors were found for EOC in this population-based cohort study that also presents nearly accurate long-term survival owing to the nonselective nature and completeness regarding patients and follow-up of the study.

Entities:  

Mesh:

Year:  2009        PMID: 19258952     DOI: 10.1111/IGC.0b013e3181991b13

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.

Authors:  Camilla Praestegaard; Allan Jensen; Signe M Jensen; Thor S S Nielsen; Penelope M Webb; Christina M Nagle; Anna DeFazio; Estrid Høgdall; Mary Anne Rossing; Jennifer A Doherty; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten Moysich; Roberta B Ness; Robert Edwards; Keitaro Matsuo; Satoyo Hosono; Ellen L Goode; Stacey J Winham; Brooke L Fridley; Daniel W Cramer; Kathryn L Terry; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Lisa E Paddock; Leon F Massuger; Nicolas Wentzensen; Paul Pharoah; Honglin Song; Alice Whittemore; Valerie McGuire; Weiva Sieh; Joseph Rothstein; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Alexandra Gentry-Maharaj; Anna H Wu; Celeste L Pearce; Malcolm Pike; Alice W Lee; Rebecca Sutphen; Jenny Chang-Claude; Harvey A Risch; Susanne K Kjaer
Journal:  Int J Cancer       Date:  2017-01-24       Impact factor: 7.396

2.  Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.

Authors:  Fanny Dao; Brooke A Schlappe; Jill Tseng; Jenny Lester; Alpa M Nick; Susan K Lutgendorf; Scott McMeekin; Robert L Coleman; Kathleen N Moore; Beth Y Karlan; Anil K Sood; Douglas A Levine
Journal:  Gynecol Oncol       Date:  2016-03-11       Impact factor: 5.482

3.  Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years.

Authors:  Zeinab Hamidou; Sylvain Causeret; Tienhan S Dabakuyo; Julie Gentil; Laurent Arnould; Patrick Roignot; Thierry Altwegg; Marie-Laure Poillot; Franck Bonnetain; Patrick Arveux
Journal:  BMC Cancer       Date:  2010-11-10       Impact factor: 4.430

4.  Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Authors:  C A Hamilton; A Miller; Y Casablanca; N S Horowitz; B Rungruang; T C Krivak; S D Richard; N Rodriguez; M J Birrer; F J Backes; M A Geller; M Quinn; M J Goodheart; D G Mutch; J J Kavanagh; G L Maxwell; M A Bookman
Journal:  Gynecol Oncol       Date:  2017-11-28       Impact factor: 5.482

5.  Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database.

Authors:  Shi-Ping Yang; Hui-Luan Su; Xiu-Bei Chen; Li Hua; Jian-Xian Chen; Min Hu; Jian Lei; San-Gang Wu; Juan Zhou
Journal:  JMIR Public Health Surveill       Date:  2021-11-17

6.  Genomic aberrations relate early and advanced stage ovarian cancer.

Authors:  Afra Zaal; Wouter J Peyrot; P M J J Berns; Maria E L van der Burg; Jan H W Veerbeek; J Baptist Trimbos; Isabelle Cadron; Paul J van Diest; Wessel N van Wieringen; Oscar Krijgsman; Gerrit A Meijer; Jurgen M J Piek; Petra J Timmers; Ignace Vergote; René H M Verheijen; Bauke Ylstra; Ronald P Zweemer
Journal:  Cell Oncol (Dordr)       Date:  2012-05-12       Impact factor: 6.730

7.  Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.

Authors:  Rikki A Cannioto; Michael J LaMonte; Linda E Kelemen; Harvey A Risch; Kevin H Eng; Albina N Minlikeeva; Chi-Chen Hong; J Brian Szender; Lara Sucheston-Campbell; Janine M Joseph; Andrew Berchuck; Jenny Chang-Claude; Daniel W Cramer; Anna DeFazio; Brenda Diergaarde; Thilo Dörk; Jennifer A Doherty; Robert P Edwards; Brooke L Fridley; Grace Friel; Ellen L Goode; Marc T Goodman; Peter Hillemanns; Estrid Hogdall; Satoyo Hosono; Joseph L Kelley; Susanne K Kjaer; Rüdiger Klapdor; Keitaro Matsuo; Kunle Odunsi; Christina M Nagle; Catherine M Olsen; Lisa E Paddock; Celeste L Pearce; Malcolm C Pike; Mary A Rossing; Barbara Schmalfeldt; Brahm H Segal; Elizabeth A Szamreta; Pamela J Thompson; Chiu-Chen Tseng; Robert Vierkant; Joellen M Schildkraut; Nicolas Wentzensen; Kristine G Wicklund; Stacey J Winham; Anna H Wu; Francesmary Modugno; Roberta B Ness; Allan Jensen; Penelope M Webb; Kathryn Terry; Elisa V Bandera; Kirsten B Moysich
Journal:  Br J Cancer       Date:  2016-06-14       Impact factor: 7.640

8.  Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity.

Authors:  Janisha Silva Raju; Nor Haslinda Abd Aziz; Ghofraan Abdulsalam Atallah; Chew Kah Teik; Mohamad Nasir Shafiee; Muhammad Fakhri Mohd Saleh; Ravichandran Jeganathan; Reena Rahayu Md Zin; Nirmala Chandralega Kampan
Journal:  Diagnostics (Basel)       Date:  2021-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.